In patients with severe aortic stenosis (AS) and preserved left ventricular ejection fraction (LVEF), low flow (LF) is currently defined using Doppler-echocardiography by a stroke volume index (SVi)<35 mL/m 2 . However, the relationship between LF and outcome remains unclear as data on normal reference values defining LF are scarce, and previous studies did not explore the risk associated with other SVi cut-points. We analysed the relationship between LF and mortality in severe AS to establish prognostic LF values associated with mortality risk. 
Introduction
Current guidelines define severe aortic stenosis (AS) as an aortic valve area (AVA) < 1 cm 2 (>0.6 cm/m 2 ) and a peak aortic jet velocity (V max ) > _4 m/s, or a mean pressure gradient > _40 mmHg in patients with preserved (> _50%) left ventricular ejection fraction (LVEF). 1, 2 In patients with AS and preserved LVEF, low flow (LF) is currently defined 1,2 by a stroke volume index (SVi) < 35 mL/m 2 based on several studies that have arbitrarily used this cut-off value. [3] [4] [5] Previous studies have suggested that LF, defined as SVi < 35 mL/m 2 is associated with poor prognosis in asymptomatic and symptomatic patients with low-gradient (LG) AS and preserved LVEF. 3, [5] [6] [7] [8] The Doppler-derived measurement of stroke volume (SV) at the aortic annulus has shown good correlation with invasive calculations [9] [10] [11] and is widely used in clinical practice and recommended by guidelines. 12 However, published normal reference values in healthy individuals are scarce. [13] [14] [15] The relationship between SV and mortality has not been described across the whole spectrum of patients with severe AS and, therefore, the SVi value delineating a subgroup of LF severe AS at high risk of death remains unclear. Moreover, non-indexed SV values associated with high mortality risk have never been reported. This study analyses the relationship between SV and SVi measured at the time of AS diagnosis and all-cause mortality during follow-up. We enrolled in two tertiary centres (Amiens, and Lille, France) patients with severe AS and preserved LVEF and aimed to evaluate the predictive value of SV and SVi on outcome with medical and surgical management and establish prognostic LF values associated with mortality risk.
Methods

Patient population
Between 2000 and 2015, patients > _18 years of age diagnosed with > _mild AS (aortic leaflet calcification with reduction in systolic movements and V max > 2.5 m/s) were prospectively identified and included in an electronic database. We excluded: (i) >mild aortic and/or mitral regurgitation; (ii) prosthetic valves, congenital heart disease, supravalvular or subvalvular AS, or dynamic LV outflow tract obstruction; (iii) mitral stenosis; and (iv) patients who refused to participate in the study. This analysis included 1450 patients with severe AS [defined as AVA < 1 cm 2 and/or AVA normalized to body surface area (BSA) <0.6 cm 2 ] and preserved LVEF. Eighty-one patients were excluded because of missing data. Clinical and demographic baseline characteristics were collected. 16 An index summating the patient's individual comorbidities was calculated. 16 
Controls
Using the echocardiography databases, we retrospectively identified between 2014 and 2016, 1645 consecutive individuals > _18 years of age with normal echocardiograms. These individuals had normal blood pressure, and no personal history of cardiovascular disease. All echocardiograms were validated as normal by physicians experienced in transthoracic echocardiography. We obtained institutional review board authorizations prior to conducting the study. The study was conducted in accordance with institutional policies, national legislation, and the revised Helsinki declaration. Patients gave informed written consent prior to participation in the study.
Echocardiography
All patients underwent a comprehensive Doppler-echocardiography study, using commercially available ultrasound systems. Aortic flow was recorded using continuous-wave Doppler, systematically in several acoustic windows (apical 5-chamber, right parasternal, suprasternal, epigastric). 16 Stroke volume was calculated by multiplying the LV outflow tract area with the LV outflow tract time-velocity integral. 3, 17 The LV outflow tract diameter was measured in zoomed parasternal long-axis views in early systole at the level of aortic cusp insertion. 18 The LV outflow tract time-velocity integral was recorded from the apical 5-chamber view, with the sample volume positioned about 5 mm proximal to the aortic valve. 17 Aortic valve area and SV were indexed to BSA. When patients were in sinus rhythm, three cardiac cycles were averaged for all measures. For patients in atrial fibrillation, five cardiac cycles were averaged.
Treatment decision and follow-up
The majority of patients were followed in the outpatient clinics of the two tertiary centres. The others were followed in public hospitals or private practices by referring cardiologists working together with the tertiary centres. Information on follow-up was obtained by direct patient interview or by repeated follow-up letters and questionnaires to physicians, patients and (if necessary) next of kin. Ninety-three per cent of patients were followed up to 2 years or death. Follow-up was complete up to death or to the end of the study in 1295 patients (89% Estimated survival rates and 95% confidence intervals (95% CIs) were estimated according to the Kaplan-Meier method and compared with two-sided log-rank tests. Univariate and multivariable analyses of allcause mortality were performed using Cox proportional hazards models. We did not use model-building techniques and entered in the models covariates of potential prognostic impact on an epidemiological basis. These covariates were: age, sex, body mass index, Charlson comorbidity index (not including age), symptoms (New York Heart Association Class II-IV dyspnoea, angina, or syncope), history of hypertension, coronary artery disease, atrial fibrillation, systolic blood pressure at baseline, V max , AVA, LVEF, and indexed LV mass. The effect of aortic valve replacement (AVR) on outcome was analysed as a time-dependent covariate using the entire follow-up. Age, body mass index, comorbidity index, systolic blood pressure, V max , AVA, LVEF, and indexed LV mass were used as continuous variables. The proportional hazards assumption was confirmed using statistics and graphs based on the Schoenfeld residuals. To show the additive value of the flow measurements, we computed the likelihood ratios of the following models: Model 1 including clinical factors, Model 2 including clinical factors, V max , AVA, LVEF, and indexed LV mass, and Models 3 and 4 including clinical factors, V max , AVA, LVEF, indexed LV mass, and flow quantification (SVi or SV). We compared the models using the global v 2 statistic, the Akaike Information Criterion and the Harrell's C concordance statistic. Additionally, we evaluated the goodness-of-fit of the models using the Gronnesby-Brogan test. We conducted subgroup analyses to determine the homogeneity of the association of SVi and SV and mortality. First, we estimated the effect of SVi and SV on mortality in each subgroup using a Cox univariate model and then formally tested for firstorder interactions entering interaction terms, separately for each subgroup. A significance level of 0.05 was assumed for all tests. 
Results
Stroke volume by Doppler echocardiography in normal individuals
In Table 1) . The baseline characteristics of the study patients stratified according to non-indexed SV are presented in the Supplementary material online, Table S1 .
Outcome impact of stroke volume
Clinical management and follow-up Median (25th, 75th percentile) overall follow-up was 38 (17-69) months. The total number of deaths recorded during follow-up was 440. AVR was performed in 1072 patients (74%) by surgical (n = 970, 90.5%) or percutaneous (n = 102, 9.5%) techniques. Aortic bioprostheses were used in 879 patients (82%). One hundred and sixty patients had at least one associated coronary artery bypass graft at the time of AVR. AVR rates were lower in patients with LF (76% for SVi > 35 mL/m 2 , 72% for SVi 30-35 mL/m 2 , and 62% for SVi < 30 mL/ m 2 , P-value 0.001). Figure 1A) . On multivariable analysis, after adjustment for age, sex, body mass index, Charlson comorbidity index, systolic blood pressure, symptoms, hypertension, coronary artery disease, atrial fibrillation, LVEF, V max , AVA, and indexed LV mass, the risk of death associated with SVi < 30 mL/m 2 Figure 1B) . Five-year survival of patients with SVi < 30 mL/m 2 was significantly lower than that of patients with SVi > _ 30 mL/m 2 (53 ± 4% vs. 71 ± 2%; P < 0.001; Figure 2A ).
Outcome impact of stroke volume index
Compared to SVi > _ 30 mL/m 2 , the adjusted mortality risk of patients with SVi < 30 mL/m 2 was considerable ( Figure 3A ). There were Table S4 ).
Outcome impact of stroke volume Estimated 5-year survival was 75 (72-79)% for SV > 70 mL, 69 (64-74)% for SV 55-70 mL, and 49 (39-55)% for SV < 55 mL (overall P-value <0.001, Figure 4A ). On multivariable analysis, after adjustment for covariates of prognostic importance, SV < 55 mL was strongly and independently associated with all-cause death [adjusted HR 1.81 (1.30-2.52); Table 2 ]. The risk of death associated with SV 55-70 mL was comparable to that of patients with SV > 70 mL ( Table 2 ; Supplementary material online, Table S2 ). After further adjustment for surgery, SV < 55 mL remained independently predictive of mortality [adjusted HR 1.84 (1.32-2.58]; Table 2 ; Figure 4B ], while the adjusted mortality risk of patients with SV 55-70 mL and with SV > 70 mL was similar ( Table 2 ; Figure 4B ). Five-year survival of patients with SV < 55 mL was significantly lower than that of patients with SV > _ 55 mL (49 ± 4% vs. 72 ± 2%; P < 0.001; Figure 5A ). Compared to SV > _ 55 mL, the adjusted mortality risk of patients with SV < 55 mL was considerable ( Table 2 ; Figure 5B ). Model performance improved significantly when SV < 55 mL was added to a multivariable model including clinical factors and echo-Doppler parameters (Supplementary material online, Table S3 ). When SV was further stratified above the 70 mL cut-point (Supplementary material online, Figure S1 ), on multivariable analysis, SV < 55 mL remained associated with increased mortality compared to SV > _ 85 mL [adjusted HR 1.66 (1.12-2.48)] while mortality risk was similar for SV 55-70 mL/m 2 and > _85 mL [adjusted HR 1.14 (0.83-1.57)] and for SV 70-85 mL and > _85 mL [adjusted HR 1.04 (0.78-1.22)]. The 70 mL SV cut-point had a sensitivity of 46.7 ± 2.7% and a specificity of 35.1 ± 2.7% for predicting 5-year mortality. The 55 mL cut-point had 77.7 ± 2.3% sensitivity and 13.1 ± 1.5% specificity while for the 85 mL cut-point sensitivity and specificity were 20.7 ± 2.2% and, respectively, 69.7 ± 2.2%. We further explored the association of SV < 55 mL and mortality risk in subgroups of patients with severe AS ( Figure 3B ). The only significant interaction was with BSA > 2.0 m 2 ( Figure 3B ). There was no interaction between small (<1.6 m 2 ) BSA and the prognostic effect of SV < 55 mL (P for interaction 0.38). In the subgroup with LG severe AS, mortality risk was similar for SV 55-70 mL and >70 mL, while SV < 55 mL was significantly associated with excess mortality (Supplementary material online, Table S4 ).
Discussion
The present study based on a large registry of patients with severe AS and preserved LVEF managed in routine clinical practice demonstrates that baseline SVi and SV assessed by Dopplerechocardiography are major independent determinants of long-term outcome under medical and surgical management. First, the effect of LF on mortality is powerful and remains valid after adjustment for factors known as major determinants of outcome such as age, comorbidity, symptoms, blood pressure, atrial fibrillation, coronary artery disease, LVEF, V max , and surgery. Second, LF defined by SVi < 30 mL/ m 2 or non-indexed SV < 55 mL (observed in 13% and respectively 14% of the study population) is associated with more than 50% increase of the risk of all-cause mortality during follow-up, irrespective of baseline characteristics such as symptoms, pressure gradients across the aortic valve and management type. but does not imply excess mortality risk compared to SVi > 35 mL/ m 2 and SV > 70 mL. Finally, we report for the first time the link between non-indexed SV and mortality, and show that the 55 mL value can be reliably used in the vast majority of patients (with the exception of those with large body size). Thus, SVi < 30 mL/m 2 and SV < 55 mL identify patients with severe AS and preserved LVEF at high risk of death and should be used in clinical practice for risk stratification proposes.
The assessment of the SV is routinely performed by Dopplerechocardiography at the level of the LV outflow tract. 12 The
Doppler-derived measurement of SV has shown good correlation with invasive calculations [9] [10] [11] and is widely used in clinical practice and recommended by guidelines. 12 Despite the widespread use of Doppler-derived SV, published normal reference values in healthy individuals are scarce. [13] [14] [15] In the report by Chin et al., 13 Covariates used for multivariable analysis are the same as in Figure 1B . SVi, stroke volume index. Moreover, almost 40% of these individuals had SVi < 35 mL/m 2 , suggesting that Doppler-derived LF state as currently defined 1,2 is frequent in the healthy general population. The SVi < 35 mL/m 2 value is used to define LF in severe AS, although this cut-point has been arbitrarily defined. [3] [4] [5] According to the data presented above and to previous reports, 13-15 the 35 mL/m 2 value is in the normal range.
Therefore, the 35 mL/m 2 value is in our opinion, too high, and a lower value (i.e. 30 mL/m 2 ) should be used for risk stratification.
Previous studies have reported that SVi < 35 mL/m 2 is associated with poor prognosis in asymptomatic and symptomatic patients with LG AS and preserved LVEF. [3] [4] [5] [6] 19 SVi < 35 mL/m 2 was identified as a strong predictor of outcome in a retrospective study including patients with at least mild AS 7 and in patients with mild-to-moderate AS included in the Simvastatin Ezetimibe in Aortic Stenois (SEAS) study. 8 In the Placement of Aortic Transcatheter Valves (PARTNER) trial and registry, LF (defined as SVi < 35 mL/m 2 ) at baseline was independently predictive of mortality, 20 while severe LF at discharge (defined as the lowest tertile of discharge SVi; mean value 23.1 mL/m 2 ) was a strong predictor of poor outcome after transcatheter AVR despite the observed overall beneficial effect of the technique. 21 The present study Figure 1B . HR, hazard ratio; SV, stroke volume.
